Additionally, whilst no significant change was observed in cancer cell proliferation in the TPCS, an increase in active caspase-3+ apoptotic cells was observed following treatment with 20 μM sorafenib, reflective of the in vivo immunohistochemical data (Figures 3H, I). This evidence concerns the gene CASP3 and cancer.